EDIT

Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing genome editing therapies using CRISPR technology. The company aims to discover, develop, manufacture, and commercialize precision genomic medicines for serious diseases, including genetic and blood disorders such as sickle cell disease and transfusion-dependent beta thalassemia. Editas operates primarily in the United States, with its headquarters in Cambridge, Massachusetts, and a commitment to advancing transformative treatments for patients globally.